Resmed Inc (RMD) 59.46 $RMD
Kaiser Permanente Study: ResMed Digital Platform Drives CPAP Adherence
PR Newswire - Mon Jun 13, 8:00AM CDT
Remote monitoring and automated coaching from ResMed (NYSE: RMD) significantly improve the use of continuous positive airway pressure therapy for patients with obstructive sleep apnea, according to an independent Kaiser Permanente study presented last night at the SLEEP conference in Denver - the largest-ever randomized, controlled study on OSA in the United States.
RMD: 59.46 (-0.34)
Technical Pulse on Medical Appliances & Equipment Stocks -- St. Jude Medical, ResMed, Steris, and Varian Medical Systems
PR Newswire - Mon Jun 06, 8:00AM CDT
On Friday, June 03, 2016, the NASDAQ Composite ended the trading session at 4,942.52, down 0.58%; the Dow Jones Industrial Average lost 0.18% to finish at 17,807.06; and the S&P 500 closed at 2,099.13, down 0.29%. ActiveWallSt.com has initiated coverage on the following equities: St. Jude Medical Inc. (NYSE: STJ), ResMed Inc. (NYSE: RMD), Steris PLC (NYSE: STE), and Varian Medical Systems Inc. (NYSE: VAR). Learn more about these stocks by accessing their free trade alerts at:
VAR: 84.24 (-1.06), STE: 68.47 (-2.27), RMD: 59.46 (-0.34), STJ: 77.10 (-0.25), MDSY: 1.51 (+0.01)
ResMed Posts Mixed Q3 Results, Brightree Buyout on Track
Zacks Equity Research - Zacks Investment Research - Thu May 26, 7:35AM CDT
ResMed (RMD) posted a lackluster third-quarter fiscal 2016. Nevertheless, ResMed's segmental as well as geographical performance was strong.
BSX: 22.99 (-0.03), SRDX: 24.03 (+0.84), BAX: 44.68 (+0.19), RMD: 59.46 (-0.34)
ResMed: Positive CAT-HF Study Results to Drive ASV Sales
Zacks Equity Research - Zacks Investment Research - Wed May 25, 7:51AM CDT
The positive CAT-HF study results encourage us to expect a rise in demand for the wide range of products offered by ResMed (RMD) in the respiratory care market.
BSX: 22.99 (-0.03), SRDX: 24.03 (+0.84), BAX: 44.68 (+0.19), RMD: 59.46 (-0.34)
Adaptive Servo-ventilation (ASV) Therapy Suggests Positive Cardiovascular Outcomes for People with Sleep-Disordered Breathing and Heart Failure With Preserved Ejection Fraction In Phase II Study
PR Newswire - Sun May 22, 1:40AM CDT
FLORENCE, Italy, May 22, 2016 /PRNewswire/-- ResMed (NYSE: RMD) today announced primary results from a multicenter, randomized controlled Phase II trial known as CAT-HF presented at the European Society of Cardiology's 2016 Annual Heart Failure Congress. CAT-HF assessed whether the treatment of moderate to severe sleep-disordered breathing (obstructive or central sleep apnea) with adaptive servo-ventilation (ASV) therapy could improve cardiovascular outcomes in patients who were hospitalized for a sudden worsening of their heart failure symptoms (acute decompensated heart failure) over six months.
RMD: 59.46 (-0.34)
ResMed Life Support Ventilators to Join World's Largest Remote Patient Monitoring Network
PR Newswire - Mon May 16, 5:30AM CDT
Patients using in-home life support and their clinicians are about to enjoy the latest in home health technology, remote patient monitoring, thanks to the world's first cellular, cloud-connected in-home life support ventilators.
RMD: 59.46 (-0.34)
International Trade Commission to Investigate Chinese Manufacturer BMC Medical's Infringement of ResMed Patents
PR Newswire - Fri May 13, 5:00AM CDT
ResMed (NYSE:RMD) the world's leading tech-driven medical device company and innovator in sleep-disordered breathing and respiratory care, announced today that the United States International Trade Commission (ITC) has accepted its request to investigate alleged infringement of its patented technology by Chinese medical device manufacturer BMC Medical Co., Ltd. and its U.S. distributor, 3B Medical.
RMD: 59.46 (-0.34)
Upgrade Alert for ResMed (RMD)
Comtex SmarTrend(R) - Thu Apr 28, 3:47AM CDT
ResMed (NYSE:RMD) was upgraded from Underperform to Neutral at Macquarie (pre-open) today. The stock closed yesterday at $56.65 on volume of 2.6 million shares, above average daily volume of 963,000. ResMed share prices have moved between a 52-week high of $66.62 and a 52-week low of $48.99 and closed yesterday at 16% above that low price at $56.65 per share. The 200-day and 50-day moving averages have moved 0.07% higher and 0.16% higher over the past week, respectively.
RMD: 59.46 (-0.34)
Downgrade Alert for ResMed (RMD)
Comtex SmarTrend(R) - Thu Apr 28, 3:45AM CDT
ResMed (NYSE:RMD) was downgraded from Overweight to Neutral at Piper Jaffray today. The stock closed yesterday at $56.65 on volume of 2.6 million shares, above average daily volume of 963,000. In the past 52 weeks, shares of ResMed have traded between a low of $48.99 and a high of $66.62 and closed yesterday at $56.65, which is 16% above that low price. Over the last five market days, the 200-day moving average (MA) has remained constant while the 50-day MA has advanced 0.2%.
RMD: 59.46 (-0.34)
SmarTrend Watching for Potential Rebound in Shares of ResMed After 7.27% Loss
Comtex SmarTrend(R) - Wed Apr 27, 2:57PM CDT
ResMed (NYSE:RMD) traded in a range yesterday that spanned from a low of $56.39 to a high of $58.06. Yesterday, the shares fell 7.3%, which took the trading range below the 3-day low of $59.94 on volume of 1.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
RMD: 59.46 (-0.34)
ResMed (RMD) Q3 Earnings Miss, Revenues Meet Estimates
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 8:04AM CDT
ResMed 9RMD) ended third-quarter fiscal 2016 on a modest note. Nevertheless, ResMed posted positive year-over-year growth as far as its segmental and geographical results are concerned.
BSX: 22.99 (-0.03), CSII: 18.23 (-0.13), RMD: 59.46 (-0.34), OFIX: 45.79 (-0.37)
Simavita Announces Changes to the Board and Management; Strong Support from Existing Shareholders for the Company; Additional Financing / Issue of Notes
Marketwired - Wed Apr 27, 7:02AM CDT
Simavita Limited ("Simavita" or the "Company"
(TSX VENTURE: SV)(ASX: SVA) today announced that the Company, supported by its major shareholders, has completed a review of its Board, operations; executive management and working capital.
RMD: 59.46 (-0.34), SV.VN: 0.035 (-0.005), SVA: 5.93 (-0.02)
ResMed misses 3Q profit forecasts
Automated Insights - Tue Apr 26, 4:29PM CDT
SAN DIEGO (AP) _ ResMed Inc. (RMD) on Tuesday reported fiscal third-quarter profit of $88.5 million.
RMD: 59.46 (-0.34)
ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2016
PR Newswire - Tue Apr 26, 3:05PM CDT
ResMed Inc. (NYSE: RMD) today announced results for its quarter ended March 31, 2016. Revenue for the quarter was $453.9 million, a 7 percent increase compared with the quarter ended March 31, 2015; this is a 9 percent increase on a constant currency basis.
RMD: 59.46 (-0.34)
Top 4 Sales Growth Stocks
Zacks Equity Research - Zacks Investment Research - Mon Apr 18, 12:25PM CDT
Sales growth is an important indicator of a company's health and ability to sustain its business.
GILD: 83.98 (-0.47), TROW: 71.82 (-1.01), RMD: 59.46 (-0.34), FPRX: 42.97 (+0.10)
CVS Health Strong on Omnicare Buyout, Integration Prospects
Zacks Equity Research - Zacks Investment Research - Tue Apr 12, 1:40PM CDT
On Apr 12, 2016, we issued an updated research report on Rhode Island-based pharmacy retail giant CVS Health Corp. (CVS).
BAX: 44.68 (+0.19), RMD: 59.46 (-0.34), CVS: 95.91 (-0.76), OSUR: 6.69 (-1.09)
Amedisys Poised on Balanced Growth, Strategic Buyouts
Zacks Equity Research - Zacks Investment Research - Tue Apr 12, 1:35PM CDT
On Apr 11, 2016, we issued an updated research report on Amedisys Inc. (AMED).
AFAM: 41.40 (-0.71), CSII: 18.23 (-0.13), RMD: 59.46 (-0.34), AMED: 50.59 (-1.21)
ResMed: Strong Cash Balance, Product Portfolio Drive Growth
Zacks Equity Research - Zacks Investment Research - Fri Apr 08, 1:50PM CDT
ResMed (RMD) currently has a strong cash balance, as evident from $269.5 million in cash flow from operations generated during the fiscal 2016 second quarter
BAX: 44.68 (+0.19), LMAT: 14.85 (-0.18), RMD: 59.46 (-0.34), OFIX: 45.79 (-0.37)
ResMed Set to Possibly Pullback After Yesterday's Rally of 2.16%
Comtex SmarTrend(R) - Thu Mar 31, 2:59PM CDT
ResMed (NYSE:RMD) traded in a range yesterday that spanned from a low of $56.84 to a high of $58.21. Yesterday, the shares gained 2.2%, which took the trading range above the 3-day high of $57.23 on volume of 305,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
RMD: 59.46 (-0.34)
Kaiser Permanente Study: ResMed Digital Platform Drives CPAP Adherence
PR Newswire - Mon Jun 13, 8:00AM CDT
Remote monitoring and automated coaching from ResMed (NYSE: RMD) significantly improve the use of continuous positive airway pressure therapy for patients with obstructive sleep apnea, according to an independent Kaiser Permanente study presented last night at the SLEEP conference in Denver - the largest-ever randomized, controlled study on OSA in the United States.
RMD: 59.46 (-0.34)
Technical Pulse on Medical Appliances & Equipment Stocks -- St. Jude Medical, ResMed, Steris, and Varian Medical Systems
PR Newswire - Mon Jun 06, 8:00AM CDT
On Friday, June 03, 2016, the NASDAQ Composite ended the trading session at 4,942.52, down 0.58%; the Dow Jones Industrial Average lost 0.18% to finish at 17,807.06; and the S&P 500 closed at 2,099.13, down 0.29%. ActiveWallSt.com has initiated coverage on the following equities: St. Jude Medical Inc. (NYSE: STJ), ResMed Inc. (NYSE: RMD), Steris PLC (NYSE: STE), and Varian Medical Systems Inc. (NYSE: VAR). Learn more about these stocks by accessing their free trade alerts at:
VAR: 84.24 (-1.06), STE: 68.47 (-2.27), RMD: 59.46 (-0.34), STJ: 77.10 (-0.25), MDSY: 1.51 (+0.01)
ResMed Posts Mixed Q3 Results, Brightree Buyout on Track
Zacks Equity Research - Zacks Investment Research - Thu May 26, 7:35AM CDT
ResMed (RMD) posted a lackluster third-quarter fiscal 2016. Nevertheless, ResMed's segmental as well as geographical performance was strong.
BSX: 22.99 (-0.03), SRDX: 24.03 (+0.84), BAX: 44.68 (+0.19), RMD: 59.46 (-0.34)
ResMed: Positive CAT-HF Study Results to Drive ASV Sales
Zacks Equity Research - Zacks Investment Research - Wed May 25, 7:51AM CDT
The positive CAT-HF study results encourage us to expect a rise in demand for the wide range of products offered by ResMed (RMD) in the respiratory care market.
BSX: 22.99 (-0.03), SRDX: 24.03 (+0.84), BAX: 44.68 (+0.19), RMD: 59.46 (-0.34)
Adaptive Servo-ventilation (ASV) Therapy Suggests Positive Cardiovascular Outcomes for People with Sleep-Disordered Breathing and Heart Failure With Preserved Ejection Fraction In Phase II Study
PR Newswire - Sun May 22, 1:40AM CDT
FLORENCE, Italy, May 22, 2016 /PRNewswire/-- ResMed (NYSE: RMD) today announced primary results from a multicenter, randomized controlled Phase II trial known as CAT-HF presented at the European Society of Cardiology's 2016 Annual Heart Failure Congress. CAT-HF assessed whether the treatment of moderate to severe sleep-disordered breathing (obstructive or central sleep apnea) with adaptive servo-ventilation (ASV) therapy could improve cardiovascular outcomes in patients who were hospitalized for a sudden worsening of their heart failure symptoms (acute decompensated heart failure) over six months.
RMD: 59.46 (-0.34)
ResMed Life Support Ventilators to Join World's Largest Remote Patient Monitoring Network
PR Newswire - Mon May 16, 5:30AM CDT
Patients using in-home life support and their clinicians are about to enjoy the latest in home health technology, remote patient monitoring, thanks to the world's first cellular, cloud-connected in-home life support ventilators.
RMD: 59.46 (-0.34)
International Trade Commission to Investigate Chinese Manufacturer BMC Medical's Infringement of ResMed Patents
PR Newswire - Fri May 13, 5:00AM CDT
ResMed (NYSE:RMD) the world's leading tech-driven medical device company and innovator in sleep-disordered breathing and respiratory care, announced today that the United States International Trade Commission (ITC) has accepted its request to investigate alleged infringement of its patented technology by Chinese medical device manufacturer BMC Medical Co., Ltd. and its U.S. distributor, 3B Medical.
RMD: 59.46 (-0.34)
Upgrade Alert for ResMed (RMD)
Comtex SmarTrend(R) - Thu Apr 28, 3:47AM CDT
ResMed (NYSE:RMD) was upgraded from Underperform to Neutral at Macquarie (pre-open) today. The stock closed yesterday at $56.65 on volume of 2.6 million shares, above average daily volume of 963,000. ResMed share prices have moved between a 52-week high of $66.62 and a 52-week low of $48.99 and closed yesterday at 16% above that low price at $56.65 per share. The 200-day and 50-day moving averages have moved 0.07% higher and 0.16% higher over the past week, respectively.
RMD: 59.46 (-0.34)
Downgrade Alert for ResMed (RMD)
Comtex SmarTrend(R) - Thu Apr 28, 3:45AM CDT
ResMed (NYSE:RMD) was downgraded from Overweight to Neutral at Piper Jaffray today. The stock closed yesterday at $56.65 on volume of 2.6 million shares, above average daily volume of 963,000. In the past 52 weeks, shares of ResMed have traded between a low of $48.99 and a high of $66.62 and closed yesterday at $56.65, which is 16% above that low price. Over the last five market days, the 200-day moving average (MA) has remained constant while the 50-day MA has advanced 0.2%.
RMD: 59.46 (-0.34)
SmarTrend Watching for Potential Rebound in Shares of ResMed After 7.27% Loss
Comtex SmarTrend(R) - Wed Apr 27, 2:57PM CDT
ResMed (NYSE:RMD) traded in a range yesterday that spanned from a low of $56.39 to a high of $58.06. Yesterday, the shares fell 7.3%, which took the trading range below the 3-day low of $59.94 on volume of 1.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
RMD: 59.46 (-0.34)
ResMed (RMD) Q3 Earnings Miss, Revenues Meet Estimates
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 8:04AM CDT
ResMed 9RMD) ended third-quarter fiscal 2016 on a modest note. Nevertheless, ResMed posted positive year-over-year growth as far as its segmental and geographical results are concerned.
BSX: 22.99 (-0.03), CSII: 18.23 (-0.13), RMD: 59.46 (-0.34), OFIX: 45.79 (-0.37)
Simavita Announces Changes to the Board and Management; Strong Support from Existing Shareholders for the Company; Additional Financing / Issue of Notes
Marketwired - Wed Apr 27, 7:02AM CDT
Simavita Limited ("Simavita" or the "Company"
(TSX VENTURE: SV)(ASX: SVA) today announced that the Company, supported by its major shareholders, has completed a review of its Board, operations; executive management and working capital. RMD: 59.46 (-0.34), SV.VN: 0.035 (-0.005), SVA: 5.93 (-0.02)
ResMed misses 3Q profit forecasts
Automated Insights - Tue Apr 26, 4:29PM CDT
SAN DIEGO (AP) _ ResMed Inc. (RMD) on Tuesday reported fiscal third-quarter profit of $88.5 million.
RMD: 59.46 (-0.34)
ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2016
PR Newswire - Tue Apr 26, 3:05PM CDT
ResMed Inc. (NYSE: RMD) today announced results for its quarter ended March 31, 2016. Revenue for the quarter was $453.9 million, a 7 percent increase compared with the quarter ended March 31, 2015; this is a 9 percent increase on a constant currency basis.
RMD: 59.46 (-0.34)
Top 4 Sales Growth Stocks
Zacks Equity Research - Zacks Investment Research - Mon Apr 18, 12:25PM CDT
Sales growth is an important indicator of a company's health and ability to sustain its business.
GILD: 83.98 (-0.47), TROW: 71.82 (-1.01), RMD: 59.46 (-0.34), FPRX: 42.97 (+0.10)
CVS Health Strong on Omnicare Buyout, Integration Prospects
Zacks Equity Research - Zacks Investment Research - Tue Apr 12, 1:40PM CDT
On Apr 12, 2016, we issued an updated research report on Rhode Island-based pharmacy retail giant CVS Health Corp. (CVS).
BAX: 44.68 (+0.19), RMD: 59.46 (-0.34), CVS: 95.91 (-0.76), OSUR: 6.69 (-1.09)
Amedisys Poised on Balanced Growth, Strategic Buyouts
Zacks Equity Research - Zacks Investment Research - Tue Apr 12, 1:35PM CDT
On Apr 11, 2016, we issued an updated research report on Amedisys Inc. (AMED).
AFAM: 41.40 (-0.71), CSII: 18.23 (-0.13), RMD: 59.46 (-0.34), AMED: 50.59 (-1.21)
ResMed: Strong Cash Balance, Product Portfolio Drive Growth
Zacks Equity Research - Zacks Investment Research - Fri Apr 08, 1:50PM CDT
ResMed (RMD) currently has a strong cash balance, as evident from $269.5 million in cash flow from operations generated during the fiscal 2016 second quarter
BAX: 44.68 (+0.19), LMAT: 14.85 (-0.18), RMD: 59.46 (-0.34), OFIX: 45.79 (-0.37)
ResMed Set to Possibly Pullback After Yesterday's Rally of 2.16%
Comtex SmarTrend(R) - Thu Mar 31, 2:59PM CDT
ResMed (NYSE:RMD) traded in a range yesterday that spanned from a low of $56.84 to a high of $58.21. Yesterday, the shares gained 2.2%, which took the trading range above the 3-day high of $57.23 on volume of 305,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
RMD: 59.46 (-0.34)
